These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15146090)

  • 1. Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient.
    Kloner RA
    Endocrine; 2004; 23(2-3):125-9. PubMed ID: 15146090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
    Sommer F; Schulze W
    World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erectile dysfunction in patients with coronary artery disease.
    Kloner R; Padma-Nathan H
    Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction.
    Fisher WA; Rosen RC; Eardley I; Niederberger C; Nadel A; Kaufman J; Sand M
    J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
    Aversa A; Bruzziches R; Pili M; Spera G
    Curr Pharm Des; 2006; 12(27):3467-84. PubMed ID: 17017940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual function in hypertensive patients receiving treatment.
    Reffelmann T; Kloner RA
    Vasc Health Risk Manag; 2006; 2(4):447-55. PubMed ID: 17323599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the cardiologist: clinical aspects of managing erectile dysfunction.
    Hutter AM
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I3-7. PubMed ID: 15115189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 12. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats.
    Angulo J; Cuevas P; Gabancho S; Gonzalez-Corrochano R; Videla S; Saenz de Tejada I
    J Sex Med; 2005 May; 2(3):341-6. PubMed ID: 16422865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erectile dysfunction (ED) and diabetes mellitus].
    Takahashi Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():553-7. PubMed ID: 15999768
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection.
    Jackson G
    Drugs; 2004; 64(14):1533-45. PubMed ID: 15233591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
    Matic H; McCabe MP
    Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 18. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
    Gazzaruso C
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):173-80. PubMed ID: 16509813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.